Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bausch Health Companies Inc. (NYSE:BHC) partners with the Colorectal Cancer Alliance to enhance awareness and access to colorectal cancer screenings in Philadelphia. This initiative, launching in May, targets communities with significant health disparities. Salix Pharmaceuticals, a subsidiary, will provide its bowel preparation product to individuals requiring colonoscopies, essential for early cancer detection. With colorectal cancer's 90% survival rate if detected early, this partnership aims to address socioeconomic inequities that hinder screening access. Colorectal cancer remains a leading cause of cancer deaths in the U.S., with 106,970 estimated new colon cancer cases in 2023. Salix’s commitment signifies a proactive approach to public health and cancer prevention.
Bausch Health Companies (NYSE:BHC) will release its first-quarter financial results on May 4, 2023, at 8:00 a.m. U.S. EDT.
A conference call and live webcast will follow the results announcement, where the company will discuss its business updates. All relevant materials will be provided on the Investor Relations section of Bausch Health's website prior to the call.
Participants can register for the live Q&A session to receive a PIN before the call. The company, committed to enhancing global health, develops products primarily in fields like gastroenterology, neurology, and eye health.